Related Experiment Video

Updated: Oct 26, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.0K

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1

Xiaozhen Zhang1,2,3,4,5,6, Xing Huang7,8,9,10,11,12, Jian Xu1,2,3,4,5,6

  • 1Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Nature Communications
|July 28, 2021
PubMed

Insights

Never in mitosis gene A-related kinase 2 (NEK2) stabilizes programmed cell death 1 ligand 1 (PD-L1), hindering pancreatic cancer immunotherapy. Inhibiting NEK2 enhances immune response and improves treatment efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Post-translational modifications significantly impact programmed cell death 1 ligand 1 (PD-L1) function.
  • The role of PD-L1 in pancreatic cancer therapeutic resistance is not well understood.
  • Never in mitosis gene A-related kinase 2 (NEK2) involvement in pancreatic cancer immunity requires further elucidation.

Purpose of the Study:

  • To investigate the role of NEK2 in PD-L1 stability and its impact on pancreatic cancer immunotherapy.
  • To identify NEK2 as a potential prognostic factor and therapeutic target in pancreatic cancer.
  • To explore the mechanism by which NEK2 influences PD-L1 expression and immune cell infiltration.

Main Methods:

  • Phosphorylation site analysis of PD-L1.
  • Interaction studies between NEK2 and PD-L1.
  • Assessment of NEK2 deficiency effects on PD-L1 expression and lymphocyte infiltration.
  • Evaluation of NEK2 inhibition in combination with PD-L1 blockade in preclinical models.

Main Results:

  • NEK2 phosphorylates PD-L1 at T194/T210 residues, stabilizing it and preventing degradation.
  • NEK2 deficiency suppresses PD-L1 expression and increases lymphocyte infiltration in pancreatic tumors.
  • NEK2 acts as a prognostic factor in immunologically "hot" pancreatic cancer.
  • NEK2 inhibition sensitizes tumors to PD-L1 blockade, enhancing anti-cancer immunity.

Conclusions:

  • NEK2 stabilizes PD-L1, contributing to immunotherapy resistance in pancreatic cancer.
  • Targeting NEK2 offers a promising strategy to improve pancreatic cancer immunotherapy efficacy.
  • NEK2 is an immune-dependent factor in pancreatic tumor development and progression.

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.3K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

713

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
310
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
6.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K